Journey Medical (DERM) Depreciation & Amortization (CF) (2020)

Journey Medical (DERM) reported Depreciation & Amortization (CF) of $1000.0 for Q4 2020, little changed quarter-over-quarter from $1000.0 in Q3 2020.

Journey Medical (DERM) Depreciation & Amortization (CF) (2020) Analysis & Trends

Journey Medical has reported Depreciation & Amortization (CF) for 1 years, with the latest figure at $1000.0 in Q4 2020.

For the quarter ending Q4 2020, Depreciation & Amortization (CF) changed N/A year-over-year to $1000.0; the trailing twelve-month figure through Sep 2021 stood at $1000.0 (changed N/A YoY), and the FY2020 full-year result was $5000.0, changed N/A from the prior year.
Depreciation & Amortization (CF) for Q4 2020 stood at $1000.0, roughly flat from $1000.0 in the prior quarter.
The five-year high for Depreciation & Amortization (CF) was $1000.0 in Q3 2020, with the low at $1000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Depreciation & Amortization (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn	239.00 Mn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn	119.00 Mn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn	22.60 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn	7.20 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn	172.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn	19.43 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn	21.95 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn	22.68 Mn
10	Journey Medical	168.75 Mn	141.53 Mn	9.70 Mn	-

Download Data